08/27/2024
IACT4C Announces the Appointment of Two New Board Members
The Institute for Advanced Clinical Trials for Children (IACT4C) is pleased to announce that two new members are joining its Board of Directors. The new board members bring years of experience and leadership to help advance our mission.
The new board members include:
• Stephanie Duggins Davis, MD
• Kristen Swingle, MS
Davis and Swingle join existing board members: Elizabeth Garofalo (Chair, EAG Pharma Consulting, LLC), Daniel Jorgensen (Vice Chair, former CEO of Critical Path Institute), Martha Brumfield (Secretary/Treasurer, former President and CEO of Critical Path Institute), James Pomfret (Wells Fargo Advisors), Barry Brooks (Paul Hastings, LLP), Jeff Barrett (Aridhia), Max J. Coppes (Renown Institute for Cancer), and Tamorah Lewis (Hospital for Sick Children).
“…The expertise and experience of our new board members will complement our existing leadership in advancing our mission…” said Laura Lopez, CFAO of IACT4C.
Stephanie Duggins Davis, MD
Stephanie Duggins Davis, MD is the Edward C. Curnen, Jr. Distinguished Professor and Chair for the Department of Pediatrics at UNC-Chapel Hill and the Physician-in-Chief of UNC Children’s. She has served in several high-profile national leadership roles, including President of the Society of Pediatric Research, Chair of the Board of Directors for the American Board of Pediatrics, and Chair of the Pediatric Assembly for the American Thoracic Society.
“The mission of I-ACT to accelerate drug development and reduce the wait will transform the care of children. I am truly honored to join the I-ACT Board of Directors and promote this vision.”
Kristen Swingle, MS
Kristen Swingle is the President and Chief Operating Officer of the Critical Path Institute (C-Path), bringing over 20 years of expertise in the medical and molecular sciences industry. With a robust background in product development, manufacturing, quality and regulatory affairs, and project and fiscal management, Kristen is a proven leader in driving innovation and operational excellence. In her role at C-Path, she oversees the organization’s daily operations, while spearheading the development and ex*****on of its global strategy and objectives.
"I am honored to join the board of IACT4C, an organization that is at the forefront of driving innovation in pediatric drug development,” Kristen said. “Ensuring that children have access to safe and effective treatments is a mission that resonates deeply with me. I look forward to contributing to IACT4C’s efforts to advance research and improve the lives of children through more efficient and impactful clinical trials."
IACT4C is a 501(c)(3) non-profit organization established to drive innovation to improve and expedite
pediatric drug development. IACT4C was founded in 2016 as the nation’s first nonprofit dedicated to improving pediatric drug development. It emerged from the vision of multistakeholder leaders in pediatric drug development assembled by the American Academy of Pediatrics. These stakeholders recognized that children needed better access to safe, effective pediatric drugs, biologics, and medical devices. I-ACT4C was established to meet these needs by providing the resources necessary to conduct efficient and effective pediatric clinical trials.
Go to www.iactc.org to learn more about IACT4C.
